Brazilian Pharmaceutical Market Outlook 2015-2025

ブラジルの製薬市場動向2015-2025

◆タイトル:Brazilian Pharmaceutical Market Outlook 2015-2025
◆商品コード:VGAIN502209
◆調査・発行会社:visiongain
◆発行日:2015年2月
◆ページ数:199
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:ブラジル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"ブラジルの製薬市場動向2015-2025"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Medicine sales in Brazil – your guide to trends, opportunities and revenue prospects
Do you want to assess Brazil’s pharmaceutical sales from 2015? See what lies ahead. Visiongain’s new study gives you multilevel revenue forecasts, helping your research and analysis. That report’s purpose is showing results, opportunities and future business trends.

Brazil can satisfy expectations for expanding healthcare coverage and rapid growth of its drugs market. Discover what’s possible, to 2025, for pharma companies operating in that developing country. You find business analysis, developments and potential revenues.

So please read on to explore Brazilian medical sales and discover how high that market’s revenues could go.

Trends and outlooks for that emerging healthcare market – what’s possible?
Our study covers small molecule medicines and biological drugs (biologics), including biosimilars and vaccines. From 2015 patients, healthcare providers and the pharmaceutical industry will benefit from medical progress in Brazil. You discover where, how and why.

That updated work lets you find business predictions from 2015 to 2025 at overall national and submarket levels. You discover the most lucrative parts of that market, seeing what the future holds for pharma revenue generation.

And you discover trends and analyses explaining existing and expected progress.

Forecasts and other data helping you find where the money lies in Brazil’s medical sales
To support our forecasting, our work shows you historical data, recent results, growth rates and market shares. There you investigate developments and potentials, finding what they mean and their values. You also get 53 tables, 58 charts and an exclusive interview.

Also save time and avoid struggles to find data for your research, analysis and planning. See, too, how you can help your influence, benefiting your reputation for commercial insight.

And the following sections highlight analyses our new investigation gives.

Potentials of Brazilian medical business – forecasting of that overall market and its segments
What’s Brazil’s potential? What’re the secrets of that country’s expansion of pharma sales?

There discover overall drug revenues to 2025, with discussions. Our report then shows individual sales predictions – from 2015 to 2025 – for six main submarkets:
• Patented therapies – original brands of prescription pharmaceuticals, also with prediction of vaccine and biological drug (grouped) revenues
• Generic drugs (prescription generics), also with grouped forecasting of biosimilar revenues
• OTC medicines – over-the-counter products.

The author of that report said: “The future looks promising for Brazilian pharmaceutical sales. That emerging national market is growing at a much faster rate than more mature markets, such as the US and the EU5, and will continue to do so over the next ten years.”

Hear what’s possible, then, getting a feel for that country’s medical needs and pharma business. Also gain forecasting of therapeutic applications, via separate analyses.

Diseases and their treatment – what prospects for drugs and their sellers?
The updated study also predicts revenues in Brazil for treating prominent diseases. See individual revenue forecasts to 2025 for six therapeutic categories:
• Central nervous system (CNS) products
• Cardiovascular (CV) treatments
• Alimentary and metabolic disorders therapy
• Cancer treatments (oncology)
• Infectious diseases – anti-infective agents (vaccines and antibiotics)
• Therapies for other illnesses (grouped).

How fast will those submarkets expand? And which treatment classes will give highest revenues? There you assess opportunities and potentials, seeing where you can gain.

You also investigate what stimulates and restrains sales of pharmaceuticals there.

Issues and events in Brazil – what affects drug developers, producers and sellers?
Our report also discusses forces influencing sales of medicines there from 2015 to 2025, including these forces:
• Strategies companies and public healthcare providers use to serve patients’ needs
• Efforts of domestic and foreign companies, inc. mergers and acquisitions (M&A activity), drug launches, sales ranking and Brazilian market share
• Trends in demographics, economics and epidemiology – assess rising medical needs and how to serve them
• Wholesalers, distributors and retailers of medicines – the supply chain
• Governmental policies, inc. pricing and reimbursement and other regulations.

And assess these influences, among others:
• Efforts by regions to improve medical provision, better serving populations
• Healthcare insurance – public and private – to benefit patients
• Technologies – competitors’ research and development (R&D) and manufacturing
• Technology transfer and IP protection, including action against counterfeiting
• Rising demand for biological drugs, including biosimilars (follow-on protein products)
• Brazil’s position in overall world, Latin American, BRIC nations and pharmerging countries’ pharma activity.

There you examine political, economic, social and technological questions, assessing commercial outlooks. And also strengths, weaknesses, opportunities and threats. Explore what stimulates and restrains domestic and foreign pharmaceutical companies in Brazil.

Analysis of top companies and their industry’s performance – what future sales possible?
What happens next? Our work predicts the Brazilian pharma market will reach $50.6bn in 2019 – with strong expansion. By 2025 it can become one of the world’s big drug markets.

You discover what causes that progress and what’s possible. Our study explains activities of 10 leading domestic companies, in particular, including these firms:
• EMS
• Hypermarcas
• Aché
• Eurofarma
• Cristália
• Libbs
• União Química.

You also see activities of 10 multinational (big pharma) organisations and other foreign players, including these corporations:
• Sanofi
• Novartis
• Roche
• Merck & Co.
• Pfizer
• Takeda
• Bayer.

You also see an interview with BiocadBrazil Farmaceutica. Discover the efforts of specialists, including firms making biopharmaceuticals.

Developments of leading generics and biosimilar producers and sellers
In that report you also see international manufacturers and marketers of generic drugs and biosimilars targeting Brazil, including these companies:
• Teva Pharmaceutical Industries
• Mylan
• Actavis
• Glenmark
• Valeant
• Glenmark
• Strides Arcolab
• Biocon.

【レポートの目次】

1. Report Overview
1.1 Brazil’s Pharma Market: Overview
1.2 Brazilian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Main Questions Answered by This Study
1.6 Who is This Investigation For?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQs)
1.9 Some Associated Reports
1.10 About Visiongain

2. Introduction to the Brazilian Pharmaceutical Market, 2015-2025
2.1 The Brazilian Pharmaceutical Market Overview
2.2 Generics Segment Continues to Grow in Importance
2.3 CNS the Largest Therapeutic Area in 2014
2.4 Four Domestic Companies in the Top Ten in 2014

3. Why the Brazilian Market Matters: Global Market Context
3.1 Seventh-Largest Global Economy in 2014. Fifth-Largest by 2023
3.2 Sixth-Largest Pharmaceutical Market in the World in 2013. Fourth-Largest by 2016
3.3 Brazil Represented 40% of the Latin American Pharmaceutical Market in 2014
3.4 Brazil as Part of the Pharmerging and BRIC Markets

4. Organisation of the Brazilian Pharmaceutical Market
4.1 ANVISA: The Key Institutional Body
4.2 Important Agencies Include Sindusfarma and ABRAFARMA
4.3 26% Supplement SUS with Private Healthcare in 2014
4.4 CMED Announces Average Drug Price Increase of 3.35%
4.5 RENAME Drugs and the Farmácia Popular
4.6 Private Insurance Market Growing, but Costs for Insurers Rising
4.7 M&A Led Consolidation Continues in Wholesale and Retail Sectors
4.7.1 Celesio-Owned Panpharma Still the Top Distributor
4.7.2 2013 Acquisition Makes Profarma the Largest Mixed Distributor
4.7.3 Raia Drogasil, DPSP SA and Brasil Pharma are the Leading Companies in the Retail Sector
4.8 Marketing Spend in Brazil Approaches $5bn; New Rules on Drug Advertising

5. Healthcare Variations between the Brazilian Regions
5.1 Population, Pharmaceutical Market Share and GDP by Region
5.2 South East: 42% of the National Population and 53% of Pharmaceutical Market Revenues
5.3 South: The Smallest Region, but Second-Highest GDP
5.4 North East: Second-Highest Pharmaceutical Market Share but Lowest Per Capita GDP
5.5 North: Largest and Poorest Region, Represents Less Than 5% of the Pharmaceutical Market
5.6 Midwest: Landlocked Region with the Nation’s Capital and the Lowest Population

6. Breakdown of the Brazilian Pharmaceutical Market by Product Type, 2015-2025
6.1 Forecasts for the Patented Prescription, Generic and OTC Segments of the Market, 2015-2025
6.2 Patented Prescription Drugs Forecast – Dominant Segment of the Market, But for How Much Longer?
6.2.1 PDPs: a Flagship Programme by the MoH for Bringing Down Costs
6.2.2 At 55% More Expensive, Patented Products are Struggling to Hold off the Generics Revolution
6.3 Generic Drugs Segment Forecast 2015-2025 – Continued Rapid Growth
6.3.1 Generic Pharmaceuticals: Rapid Expansion Since 2000
6.3.2 Pró-Genéricos Anticipate 45% Market Capture
6.3.3 Similares Drugs and Patient Confidence in Generics
6.3.4 Counterfeits: 7-22% of Drugs in Latin America Believed to be Affected
6.3.5 New Anti-Counterfeiting Security Measures as Part of the SNCM Due to Start in 2015 and Become Fully Operational in 2016
6.3.6 Challenges for the Brazilian Generics Market
6.4 Brazilian Biologics Market
6.4.1 Biosimilars Market in Brazil to Double in Size by 2018
6.4.2 BiocadBrazil Signs PDP for Bevacizumab and Intends to Bring More Biosimilars to Brazil
6.5 OTC Segment Forecast 2015-2025
6.5.1 OTC Segment: Analgesics, Multivitamins and Other Consumer Health Products Favoured by Brazilians
6.5.2 Multivitamins Purchased by ~15% of Brazilians
6.5.3 Coming Out From Behind the Counter
6.5.4 From Analgesics to Erectile Dysfunction Treatments, Consumer Health Treatments Remain Prominent in the Market

7. Therapeutic Areas in the Brazilian Market, 2015-2025
7.1 Forecasts for CNS, Cardiovascular, Alimentary/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2025
7.2 The Rise of Non-Communicable Diseases
7.3 Market Forecast for CNS Conditions 2015-2025
7.3.1 CNS Conditions: Currently the Largest Therapeutic Area in Brazil, Disease Burden
Comparable to US
7.3.2 Domestic Companies Target OTC and Generic CNS Treatments- Particularly in Pain
Relief
7.3.3 Foreign Competition in the Analgesics Field
7.3.4 18.4% of Brazilians Have Suffered Depression in their Lives – Represents Major
Opportunity in Antidepressant Space
7.3.5 CNS Conditions: Drivers and Restraints
7.4 Market Forecast for Cardiovascular Therapeutic Area, 2015-2025
7.4.1 Cardiovascular Diseases: Brazil’s Biggest Killer
7.4.2 Anti-hypertensives: One of the Nation’s Key Drugs- as 23% of Brazilians Suffer from
Hypertension
7.4.3 Decline of the Statins
7.4.4 Aché and Sanofi Among the Main Players in that Field
7.4.5 Cardiovascular Opportunity and Challenges
7.5 Forecast for Alimentary/Metabolic Therapeutic Area, 2015-2025
7.5.1 Alimentary/Metabolic Diseases: Affecting More Than a Quarter of Brazilians
7.5.2 Lack of Diabetes Awareness Still a Concern
7.5.3 Brazil to Localise Insulin Production by 2016
7.5.4 EMS’ Generic Esomeprazole an Important Addition
7.5.5 Capturing the Alimentary/Metabolic Disease Opportunity
7.6 Market Forecast for Cancer Medicines, 2015-2025
7.6.1 Cancer Treatment to Become the Biggest Therapeutic Area
7.6.2 ANS Introduces Significant Changes to Cancer Care from Private Health Insurance
Providers
7.6.3 Most Common Cancers in Brazil, 2014
7.6.4 Biosimilars to Help Widen Medicine Access
7.6.5 Cristália, Libbs, Roche, Sanofi, Novartis and Amgen Among the Key Players in the Field
7.6.6 Will the Oncology Therapeutic Area Realise its Potential?
7.7 Forecast for Infectious Diseases Therapeutic Area, 2015-2025
7.7.1 Infectious Diseases: Submarket Led by Vaccines and Antibiotics
7.7.2 Vaccines- Brazil not just Reliant on Multinationals, but also Innovating in its own Right
7.7.3 Brazil Managing HIV Despite IP Concerns
7.7.4 Chagas Disease and Other Infections – the Challenge
7.7.5 Infectious Disease: The Past for Brazilian Pharma?
7.8 Other Therapeutic Areas

8. Domestic Companies in the Brazilian Market, 2015-2025
8.1 The Top Ten Domestic Pharmaceutical Companies in Brazil, 2014
8.2 Purchase of Medley in 2009 Means Multinationals Still Own Bulk of Market
8.3 Domestic Firms Control 70% of Generics Market
8.4 EMS: Brazil’s Leading Pharmaceutical Company
8.4.1 Company Split into Similar, OTC, Hospital, Generic and Prescription Divisions
8.4.2 Full Production Capabilities and Significant R&D Capabilities
8.4.3 Legrand and Germed Key Subsidiaries of EMS
8.4.4 Targeting Expansion Oversees
8.5 Hypermarcas: Market Leader in OTC and Branded Generics
8.5.1 Neo Química: Ranked Third in the Generics Segment
8.5.2 Subsidiaries include Mantecorp, Brainfarma, Cosmed, DM Industria Farmacêutica
8.6 Medley: Foreign-Owned Generics Giant
8.7 Aché: A Major Acquisition Target in Brazil
8.7.1 Acheflan – the First Drug to be Developed in Brazil
8.7.2 Possible M&A in the Near Future?
8.7.3 A Large Domestic Merger an Alternative Possibility?
8.8 Eurofarma: Fifth Largest Domestic Company, with Plans to Cover 90% of Latin America
8.8.1 Relentless Latin American Acquisitions Policy
8.9 Teuto: Largest Pharmaceutical Complex in Latin America
8.9.1 Melcon Partnership and Other Growth Strategies for Teuto
8.10 Biolab Farmacêutica: Leader in the Cardiology Prescription Drugs Market
8.10.1 Joint Ventures with Merz and Emcure
8.10.2 Number of New Product Launches in 2013 and Current Pipeline in 2015
8.11 Cristalia: Largest Producer of Anaesthetics in Latin America
8.11.1 Approval From ANVISA to Produce Biosimilar Drugs
8.11.2 Leader in API Manufacturing
8.11.3 Involved in a Third of All PDPs
8.12 Libbs: Key Player in Cancer Treatment
8.12.1 Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
8.13 União Química: Huge Annual Production Capacity
8.13.1 Agreement with Novartis and Possible Public Offering in 2015
8.14 Other Domestic Players Include Moksha8 and Laboratório Daudt Oliveira
8.15 Biosimilar Collaborations
8.15.1 Bionovis: Conglomerate Developing 8 Biosimilars and Aiming to Launch First Product in 2016
8.15.2 Orygen: Conglomerate Aiming to Develop 7 Biologics
8.16 Other Biotech Players Include Biomm and Innova
8.17 Fiocruz: At the Heart of Multiple PDPs
8.18 ANVISA Reform of Brazilian Patent System

9. Multinational Companies in the Brazilian Market, 2015-2025
9.1 The Top Ten Multinational Pharmaceutical Companies in Brazil, 2014
9.2 Notable M&A Activity
9.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
9.3.1 Group Companies Include Sanofi Pasteur and Genzyme – Overall Portfolio of Over 350
Products
9.3.2 Inventory Mishandling and Dip in 2013 Results
9.4 Novartis: Only Multinational to Produce APIs in Brazil
9.4.1 PDPs and a New $342m Biotechnology Facility in the North East
9.4.2 Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
9.5 Roche: No Regrets over Staying in Brazil
9.5.1 Oncology Opportunity and Herceptin Pricing/Reimbursement
9.6 Merck & Co. – Long-Standing Presence in the Brazilian Market
9.6.1 Five Factories and Covers Five Broad Therapeutic Areas
9.6.2 Gardasil Added to SUS in 2013
9.6.3 Joint Venture with Eurofarma and Cristália
9.7 Pfizer: Targeting Emerging Market Growth via M&A
9.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
9.8 Takeda: Expanding its Brazilian Business Through Acquisitions and Aims to Launch New Drugs
9.8.1 Acquisitions of Nycomed and Multilab and Global Restructuring
9.9 Bayer: Brazil the Fifth-Largest Market for Diversified German Giant
9.9.1 OTC a Major Focus in Brazil
9.10 AstraZeneca Targets Latin America
9.10.1 Struggling with Loss of Exclusivity and Patent Infringement
9.11 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
9.11.1 Looking to Acquire OTC Brands
9.11.2 Technology Transfer Deal for Sifrol
9.12 Merck KGaA : Present in Brazil since 1923; Signs PDP with Bionovis for 8 Biosimilars.
9.12.1 Two Divisions and Multiple Therapeutic Fields
9.13 Other Notable Multinationals in Brazil
9.13.1 GlaxoSmithKline: Vaccines and Technology Transfer Opportunities
9.13.2 Abbott: Humira to Face Biosimilar Challenge in Brazil?
9.13.2.1 Abbott: Generics and Diagnostics-Led Growth Strategy
9.13.3 Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
9.13.4 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
9.13.5 Baxter: Entering Brazilian Haemophilia Market via Tech Transfer
9.13.6 Johnson & Johnson: Focusing on Consumer Health and Commodities
9.13.7 BiocadBrazil Farmaceutica
9.13.8 Amgen Signals Brazilian Intent with Bergamo Acquisition
9.13.9 Gilead, Novo Nordisk, Biogen, UCB and Meizler
9.13.10 Other Top Japanese Companies Trail Behind Takeda in Brazil
9.14 Will Multinational Generics Leaders Compete in Brazil?
9.14.1 Teva Pharmaceutical Industries: Generics Giant Targets Brazil
9.14.2 Mylan: Agila Acquisition Boosts Brazilian Strategy
9.14.3 Actavis: Newly-Merged Player May Target Brazil
9.14.4 Ranbaxy Hands Over to Daiichi, but Other Indian Companies Still in the Hunt in Brazil
9.14.5 Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
9.14.6 Valeant: M&A Drive Into the Market
9.15 Brazil as a Pharmaceutical Research Destination

10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2015-2025
10.1 Strengths, Weaknesses, Opportunities, Threats within the Market, and Political, Social, Economic and Technological Factors
10.2 A Crucial Market for the Pharmaceutical Industry
10.3 Governmental Regulation Remains an Issue
10.4 One of the Highest Pharmaceutical Tax Rates in the World
10.5 Room to Expand in Therapeutic Areas and Geographical Regions
10.6 Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
10.7 Large and Ageing Population Eager to Buy Medicines
10.8 Improved Self-Sufficiency, Biotechnological and Digital, Among Government’s Goals
10.9 Economic Conditions in 2015 – Can Economic Growth Keep Pace With Healthcare Costs?
10.10 Political Environment a Decisive Influence on the Market

11. Research Interview
11.1 Interview with Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica
11.2 On Gaining Access to the Brazilian Market, Achieving Success and Factors That Differentiate Brazil from Other Markets
11.3 The Brazilian Generics and Biosimilars Market, and Biocad’s Progress on its Biosimilars for Brazil
11.4 Biocad’s Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future
11.5 Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East
11.6 Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market- and How the 2016 Olympics will Compare
11.7 Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses will Improve in Coming Years

12. Conclusions from the Research and Analysis
12.1 Brazil Likely to Grow Faster than Most Other Top 10 Pharmaceutical Markets
12.2 Generics to be the Fastest-Growing Segment
12.3 Technology Transfer Crucial to Patented Drugs Market
12.4 Generics: Opportunities for Multinationals?
12.5 Cancer Treatment: Biggest Therapeutic and Commercial Opportunity
12.6 Concluding Remarks

List of Tables
Table 1.1 Brazilian Pharmaceutical Market Forecast by Therapy Area: Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 1.2 Brazilian Pharmaceutical Market Forecast by Therapy Area: Revenues ($bn), Annual Growth Rate (%), CAGR (%), 2019-2025
Table 1.3 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Brazilian Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2013-2018
Table 2.2 Brazilian Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2019-2025
Table 2.3 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2014
Table 2.4 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2014
Table 2.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2014
Table 3.1 World’s Largest Pharmaceutical Markets: Revenues ($bn), Market Shares (%), 2013
Table 3.2 Latin America’s Largest Pharmaceutical Markets: Revenues ($bn), Market Shares (%), 2013
Table 3.3 Pharmerging Markets
Table 4.1 Members of FenaSaúde (in Portuguese, with English in brackets), 2014
Table 6.1 Patented Prescription Drugs, Generics and OTC Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2013-2025
Table 6.2 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2018
Table 6.3 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2025
Table 6.4 Brazil Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2025
Table 6.5 Prescription Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 6.6 Selected Technology Transfer Agreements in Brazil, 1985-2013
Table 6.7 Generic Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%). 2015-2025
Table 6.8 OTC Drugs Segment Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.1 Therapeutic Areas in the Brazilian Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2013-2025
Table 7.2 Brazilian Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2018
Table 7.3 Brazilian Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2025
Table 7.4 CNS Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.5 Cardiovascular Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.6 Alimentary/Metabolic Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.7 Oncology Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.8 Infectious Diseases Therapeutic Area: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 7.9 Other Therapeutic Areas: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2015-2025
Table 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenues ($bn), Market Share (%), 2014
Table 8.2 EMS Overview, 2015
Table 8.3 Hypermarcas Overview, 2015
Table 8.4 Medley Overview, 2015
Table 8.5 Aché Overview, 2015
Table 8.6 Eurofarma Overview, 2015
Table 8.7 Teuto Overview, 2015
Table 8.8 Biolab Farmacêutica Overview, 2015
Table 8.9 Biolab Farmacêutica Pipeline, 2015
Table 8.10 Cristalia Overview, 2015
Table 8.11 Libbs Overview, 2015
Table 8.12 União Química Overview, 2015
Table 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2014
Table 9.2 Selected Multinational M&A Activity in the Brazilian Market, 2009-2012
Table 9.3 Sanofi Overview, 2015
Table 9.4 Novartis Overview, 2015
Table 9.5 Roche Overview, 2015
Table 9.6 Merck & Co Overview, 2015
Table 9.7 Pfizer Overview, 2015
Table 9.8 Takeda Overview, 2015
Table 9.9 Bayer Overview, 2015
Table 9.10 AstraZeneca Overview, 2015
Table 9.11 Boehringer Ingelheim Overview, 2015
Table 9.12 Merck KGaA Overview, 2015
Table 10.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2015
Table 10.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2015
Table 10.3 Brazilian Pharmaceutical Market: STEP Analysis, 2015

List of Figures
Figure 1.1 Product Segments Covered Within the Brazilian Pharmaceutical Market
Figure 1.2 Therapeutic Areas Covered Within the Brazilian Pharmaceutical Market
Figure 2.1 Brazilian Pharmaceutical Market: Revenues ($bn), 2013-2025
Figure 2.2 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2014
Figure 2.3 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2014
Figure 2.4 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2014
Figure 3.1 Top Ten Global Economies, 2013
Figure 3.2 Top Ten Global Economies, 2023
Figure 3.3 World’s Largest Pharmaceutical Markets by Revenue Share, 2013
Figure 3.4 Latin America’s Largest Pharmaceutical Markets by Revenue Share, 2013
Figure 3.5 BRIC Nations Pharmaceutical Market Revenues ($bn), 2013
Figure 4.1 Brazilian Public vs Private Healthcare, 2014
Figure 4.2 CMED-Mandated Average Price Rises, 2010-2014
Figure 5.1 Doctors per 1,000 Inhabitants by Brazilian Region, 2013
Figure 5.2 Brazil: Regional Population Shares (%), 2012
Figure 5.3 Brazilian Pharmaceutical Market Shares (%) by Region, 2012
Figure 5.4 Brazilian GDP Shares (%) by Region, 2012
Figure 6.1 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2018
Figure 6.2 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), Market Shares (%), 2025
Figure 6.3 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2025
Figure 6.4 Brazil: Pharmaceutical Market Breakdown: Revenues ($bn), 2013, 2018, 2025
Figure 6.5 Patented Prescription Drugs Segment Revenue ($bn), 2013-2025
Figure 6.6 Drivers and Restraints for Patented Pharmaceuticals, 2015
Figure 6.7 Generic Drugs Segment Revenue ($bn), 2013-2025
Figure 6.8 Drivers and Restraints for Generic Drugs, 2015
Figure 6.9 Brazilian Biologics Market Breakdown: Revenues ($bn) and Market Shares (%), 2013
Figure 6.10 Brazilian Biologics Market Breakdown: Revenues ($bn), 2013, 2019, 2025
Figure 6.11 OTC Drugs Segment Revenue ($bn), 2013-2025
Figure 6.12 Drivers and Restraints for OTC Drugs, 2015
Figure 7.1 Brazilian Market: Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2018
Figure 7.2 Brazilian Market: Therapeutic Area Breakdown: Revenues ($bn), Market Shares (%), 2025
Figure 7.3 Therapeutic Area Breakdown: Revenues ($bn), 2013-2025
Figure 7.4 Therapeutic Area Breakdown: Revenues ($bn), 2013, 2018, 2025
Figure 7.5 CNS Therapeutic Area: Revenues ($bn) 2013-2025
Figure 7.6 Drivers and Restraints for CNS Conditions, 2015
Figure 7.7 Cardiovascular Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.8 Drivers and Restraints for the Cardiovascular Therapy Area, 2015
Figure 7.9 Alimentary/Metabolic Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.10 Drivers and Restraints for the Alimentary/Metabolic Therapy Area, 2015
Figure 7.11 Oncology Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.12 Cancer Incidence in Males in Brazil: Numbers of Cases, 2014
Figure 7.13 Cancer Incidence in Males in Brazil: Shares (%), 2014
Figure 7.14 Cancer Incidence in Females in Brazil: Numbers of Cases, 2014
Figure 7.15 Cancer Incidence in Females in Brazil: Shares (%), 2014
Figure 7.16 Drivers and Restraints for the Oncology Therapeutic Area, 2015
Figure 7.17 Infectious Diseases Therapeutic Area: Revenues ($bn), 2013-2025
Figure 7.18 Drivers and Restraints for the Infectious Disease Therapeutic Area, 2015
Figure 7.19 Other Therapeutic Areas: Revenue ($bn), 2013-2025
Figure 8.1 Top Ten Domestic Pharmaceutical Companies in Brazil: Revenues ($bn), Market Share (%), 2014
Figure 8.2 Ache Product Portfolio Breakdown (%), 2013
Figure 9.1 Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2014
Figure 12.1 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2013-2018
Figure 12.2 Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2019-2025
Figure 12.3 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), 2013-2018
Figure 12.4 Brazilian Pharmaceutical Market Breakdown: Revenues ($bn), 2019-2025
Figure 12.5 Top Ten Companies in the Brazilian Pharmaceutical Market: Revenues ($bn), 2014
Figure 12.6 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), 2013-2018
Figure 12.7 Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenues ($bn), 2019-2025

【掲載企業】

Abbott
Abbvie
ABRAFARMA (Associação Brasileira das Redes de Farmácias e Drogarias)
Aché
Actavis
Agila Specialties
Allianz Saúde
Alteogen
American Diabetes Association
AmerisourceBergen Corporation
Amgen
Amil Participações
ANS (Agência Nacional de Saúde Suplementar)
Antaris Consulting
ANVISA
Arcolab
Arena Pharmaceuticals
Associação Brasileira de Reabilitação de Coluna
Associação Nacional de Assistencia ao Diabetico
Astellas
AstraZeneca
Athos Farma
Axis Biotec
Baxter
Bayer
Bergamo
Bill & Melinda Gates Foundation
Biocad
BiocadBrazil Farmaceutica
Biocon
Biogen
Biolab Emcure
Biolab Farmacêutica
Biomanguinhos
Biomm
Bionovis
Biosintética
BNDES (The Brazilian National Bank for Economic and Social Development)
Boehringer Ingelheim
Boiron
Brainfarma Industria e Farmaceutica
Brasil Pharma
Brazilian Medical Association
Bristol-Myers Squibb
BTG Pactual
Bunker Industria Farmaceutica
Butantan Institute
Care Plus Medicina Assistencial
CEBR (Centre for Economics and Business Research)
Ceitec
Celesio
Chemo
Claris Lifesciences
CMED (Câmara de Regulação do Mercado de Medicamentos)
Corporacion Infarmasa
Cosmed Industria de Cosmeticos e Medicamentos
Cristália
CVS Pharmacy
Daiichi Sankyo
Dimed
DM Industria Farmaceutica
DPSP SA
Eli Lilly
Emcure
Empresas Andromaco
EMS
Eurofarma
Everis
Farmácia Popular
Farmais
Farmalife
Farmanguinhos
FDA (US Food and Drug Administration)
Federal Council of Medicine
FenaSaúde
Fiocruz
Forest Laboratories
FUNED (Fundação Ezequiel Dias)
Gama Saúde
Germed Pharma
Gilead
GlaxoSmithKline (GSK)
Glenmark
Golden Cross
Grunenthal
Grupo Amil Saúde
Grupo Bradesco Saúde
Grupo Caixa Seguros Saúde
Grupo Cimed
Grupo Intermédica
Grupo SulAmérica Saúde
Grupo Tempo Saúde
GTPI (The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples)
Hapvida Assistência Médica
Health Canada
Hebron
Hemobras
Horizon Pharma
Hospital das Clínicas
Hospital Israelita Albert Einstein
Hospital Santa Catarina
Hypermarcas
IESS (Instituto de Estudos de Saúde Suplementar)
IMA Laboratories
Indar Institute
Indian Council of Medical Research
Innova
INSS (The Brazilian National Institute of Social Security)
Instituto Terapeutico Delta
Instituto Vital Brazil
InterFarma
Itauseg Saúde
Johnson & Johnson
Kantar Health
Kenya Medical Research Institute
Laboratório Daudt Oliveira
Laboratórios Klinger Do Brasil
LAFEPE (Laboratório Farmacêutico do Estado de Pernambuco)
Laprin
Lazard
Legrand
Libbs
Libbs Biotec
Luper Indústria Farmacêutica
mAbxience
Malaysian Ministry of Health
Mantecorp Industria Quimica e Farmaceutica
Marítima Saúde Seguros
Medley
Meizler Biopharma
Merck & Co.
Merck KGaA
Merz
Metlife Exclusivamente Odontológicos
Minas Gerais State Department of Health
Ministry of Health
Moksha8
MSF (Médecins sans Frontières)
Multilab Industria e Comercio de Productos Farma
Mundipharma
Mylan
Nature's Plus Farmacêutica
NeoQuimica
Novartis
Novo Nordisk
Nycomed
Odontoprev
Omint Serviços de Saúde
Oncoprod
Orygen
Otsuka
Pan American Health Organisation
Panarello
Panpharma
Pasteur Institute of France
Pele Nova
Pfizer
PharmaPraxis
Piramal
Porto Seguro - Seguro Saúde
Probiomed
Probiotica
Profarma
Profarma Speciality
Pró-Genéricos
Protalix Biotherapeutics
Quesada Farmacêutica
Quintiles
Raia Drogasil
Ranbaxy
Reckitt Benckiser
Roche
Sandoz do Brasil Indústria Farmacêutica
Sanobiol
Sanofi
Shasun Pharma
Sincamesp
Sinclair IS Pharma
Sistema Único de Saúde (SUS)
Sindusfarma
Sun
Supera Farma Laboratorios
Takeda
Tamoio
Tecpar
Telefônica Digital
Teuto
Teva Pharmaceutical Industries
The Sabin Vaccine Institute
The World Bank
TKS Farmacêutica
Torrent
UCB (Union Chimique Belge)
UERJ (Universidade do Estado do Rio de Janeiro)
União Química
UNICAMP (Universidade Estadual de Campinas)
Unimed Seguros Saúde
University of São Paulo
Valeant
Walgreens
Warc
Watson
WHO (World Health Organization)
Wockhardt
Zydus Cadila

【レポートのキーワード】

ブラジル、製薬、医薬品

★調査レポート[ブラジルの製薬市場動向2015-2025] ( Brazilian Pharmaceutical Market Outlook 2015-2025 / VGAIN502209) 販売に関する免責事項
[ブラジルの製薬市場動向2015-2025] ( Brazilian Pharmaceutical Market Outlook 2015-2025 / VGAIN502209) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆